Functional analysis of RRAS2 pathogenic variants with a Noonan-like phenotype

Takaya Iida1, Arisa Igarashi1, Kae Fukunaga1,2

  • 1Department of Genome Medicine, National Center for Child Health and Development, Tokyo, Japan.

Frontiers in Genetics
|April 11, 2024
PubMed

Insights

New research reveals that specific variants in the RRAS2 gene cause Noonan syndrome by overactivating the RAS/MAPK pathway. These gain-of-function mutations lead to developmental abnormalities, confirming RRAS2

Area of Science:

  • Molecular Biology
  • Genetics
  • Developmental Biology

Background:

  • RRAS2, a GTPase regulating cell proliferation and differentiation via the RAS/MAPK pathway, has been implicated in Noonan syndrome.
  • Previous reports identified seven pathogenic RRAS2 variants, but limited functional analysis exists.

Purpose of the Study:

  • To investigate the functional impact of novel and recurrent RRAS2 variants (p.Gly23Val and p.Gly24Glu) in patients with a Noonan-like phenotype.
  • To elucidate the role of RRAS2 gain-of-function variants in RAS signaling pathway hyperactivity and disease pathogenesis.

Main Methods:

  • Transient expression of wild-type (WT) and mutant RRAS2 in HEK293 cells, followed by Western blotting and luciferase reporter assays to assess RAS signaling activity.
  • Functional analysis in Drosophila melanogaster and zebrafish (Danio rerio) models to evaluate the in vivo effects of RRAS2 variants.

Main Results:

  • Mutant RRAS2 variants (p.Gly23Val and p.Gly24Glu) exhibited significantly increased RAS signaling pathway activity compared to WT.
  • In vivo studies demonstrated RRAS2 variant-induced lethality in Drosophila and developmental defects (oval shape, delayed jaw development) in zebrafish embryos.
  • These findings indicate hyperactivity of the RAS signaling pathway due to RRAS2 gain-of-function variants.

Conclusions:

  • Recurrent and novel RRAS2 variants identified in patients with a Noonan-like phenotype are gain-of-function mutations.
  • These RRAS2 variants lead to increased RAS signaling pathway activity, both in vitro and in vivo.
  • The study confirms that RRAS2 gain-of-function variants are causative of Noonan syndrome-like phenotypes.